NCCN临床实践指南_宫颈癌(2019.V5)英文版

NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Version 5 2019 09 16 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN Cervical Cancer Version 5 2019 September 16 2019 Continue NCCN org NCCN Guidelines Version 5 2019 Cervical Cancer Version 5 2019 09 16 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Index Table of Contents Discussion NCCN Nicole McMillian MS Continue NCCN Guidelines Panel Disclosures Gynecologic oncology Internal medicine Medical oncology Radiotherapy Radiation oncology Pathology Patient advocacy Discussion Section Writing Committee Peter Frederick MD Roswell Park Cancer Institute David K Gaffney MD PhD Huntsman Cancer Institute at the University of Utah Robert Giuntoli II MD Abramson Cancer Center at the University of Pennsylvania Ernest Han MD PhD City of Hope National Medical Center Warner K Huh MD O Neal Comprehensive Cancer Center at UAB John R Lurain III MD Robert H Lurie Comprehensive Cancer Center of Northwestern University Andrea Mariani MD Mayo Clinic Cancer Center David Mutch MD Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine Christa Nagel MD Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Nadeem R Abu Rustum MD Chair Memorial Sloan Kettering Cancer Center Catheryn M Yashar MD Vice Chair UC San Diego Moores Cancer Center Sarah Bean MD Duke Cancer Institute Kristin Bradley MD University of Wisconsin Carbone Cancer Center Susana M Campos MD MPH MS Dana Farber Brigham and Women s Cancer Center Hye Sook Chon MD Moffitt Cancer Center Christina Chu MD Fox Chase Cancer Center David Cohn MD The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute Marta Ann Crispens MD Vanderbilt Ingram Cancer Center Shari Damast MD Yale Cancer Center Smilow Cancer Hospital Oliver Dorigo MD PhD Stanford Cancer Institute Christine M Fisher MD MPH University of Colorado Cancer Center Larissa Nekhlyudov MD MPH Dana Farber Brigham and Women s Cancer Center Amanda Nickles Fader MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Steven W Remmenga MD Fred 143 Suppl 22 36 CERV 2 Footnote f revised Fertility sparing surgery for stage IB1 1B has been most validated for tumors 2 cm Small cell neuroendocrine histology and adenoma malignum gastric type adenocarcinoma also known as minimal deviation adenocarcinoma or adenoma malignum CERV 10 Footnote bb is new The accuracy of cytology results may be affected in patients who have received pelvic radiation CERV A Principles of Pathology Pathologic assessment for carcinoma Uterus Revised Longitudinal length horizontal extent in mm no longer included in FIGO 2018 staging Lymph nodes when resected Sub bullet added Isolated tumor cells are noted as pN0 i Footnote b revised Ultrastaging commonly entails thin serial sectioning of the gross SLN and review of multiple H143 Suppl 22 36 However trial data cited within this section utilized the 2009 FIGO staging system Table 1 Resection of Cervical Cancer as Primary Therapy and Table 2 Resection of Locally Recurrent Cervical Cancer With No Distant Metastasis have been extensively revised Footnote k is a new reference regarding double barrel wet colostomy Backes FJ Tierney BJ Eisenhauer EL et al Complications after double barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration time to change back Gynecol Oncol 2013 128 60 64 MS 1 The Discussion has been updated to reflect the 2018 FIGO Surgical Staging system Updates in Version 5 2019 of the NCCN Guidelines for Cervical Cancer from Version 4 2019 include CERV F New footnote d An FDA approved biosimilar is an appropriate substitute for bevacizumab was added to regimens containing bevacizumab Printed by Maria Chen on 9 17 2019 11 48 36 PM For personal use only Not approved for distribution Copyright 2019 National Comprehensive Cancer Network Inc All Rights Reserved NCCN Guidelines Version 5 2019 Cervical Cancer Version 5 2019 09 16 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Index Table of Contents Discussion UPDATES Updates in Version 2 2019 of the NCCN Guidelines for Cervical Cancer from Version 1 2019 include General Recommendation revised concurrent cisplatin platinum containing chemotherapy throughout the guidelines CERV 4 Footnote q revised Concurrent cisplatin based platinum containing chemotherapy with EBRT utilizes cisplatin as a single agent or carboplatin if cisplatin intolerant or cisp